126 related articles for article (PubMed ID: 30838787)
1. BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
Kwong A; Cheng KD; Hsue CV; Hui SK; Leung CR; Leung KA; Ngan KR; Soong SI
Asia Pac J Clin Oncol; 2019 Mar; 15 Suppl 2():20-31. PubMed ID: 30838787
[TBL] [Abstract][Full Text] [Related]
2. Genetic testing in ovarian cancer - clinical impact and current practices.
Knabben L; Imboden S; Mueller MD
Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534
[TBL] [Abstract][Full Text] [Related]
3. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
[TBL] [Abstract][Full Text] [Related]
4. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
[TBL] [Abstract][Full Text] [Related]
5. Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
Palacios J; de la Hoya M; Bellosillo B; de Juan I; Matías-Guiu X; Lázaro C; Palanca S; Osorio A; Rojo F; Rosa-Rosa JM; Cigudosa JC
Virchows Arch; 2020 Feb; 476(2):195-207. PubMed ID: 31797087
[TBL] [Abstract][Full Text] [Related]
6. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH;
J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185
[TBL] [Abstract][Full Text] [Related]
7. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
[TBL] [Abstract][Full Text] [Related]
8. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
[TBL] [Abstract][Full Text] [Related]
10. Performance of multiplicom's BRCA MASTR Dx kit on the detection of BRCA1 and BRCA2 mutations in fresh frozen ovarian and breast tumor samples.
Badoer C; Garrec C; Goossens D; Ellison G; Mills J; Dzial M; El Housni H; Berwouts S; Concolino P; Guibert-Le Guevellou V; Delnatte C; Del Favero J; Capoluongo E; Bézieau S
Oncotarget; 2016 Dec; 7(49):81357-81366. PubMed ID: 27793035
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori S; Barberis M; Bella MA; Buttitta F; Capoluongo E; Carrera P; Colombo N; Cortesi L; Genuardi M; Gion M; Guarneri V; Incorvaia L; La Verde N; Lorusso D; Marchetti A; Marchetti P; Normanno N; Pasini B; Pensabene M; Pignata S; Radice P; Ricevuto E; Sapino A; Tagliaferri P; Tassone P; Trevisiol C; Truini M; Varesco L; Russo A;
Crit Rev Oncol Hematol; 2019 Aug; 140():67-72. PubMed ID: 31176273
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
[TBL] [Abstract][Full Text] [Related]
13. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.
Moreno L; Linossi C; Esteban I; Gadea N; Carrasco E; Bonache S; Gutiérrez-Enríquez S; Cruz C; Díez O; Balmaña J
Clin Transl Oncol; 2016 Oct; 18(10):981-7. PubMed ID: 26742938
[TBL] [Abstract][Full Text] [Related]
14. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
15. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
16. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
18. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing.
De Leeneer K; Coene I; Crombez B; Simkens J; Van den Broecke R; Bols A; Stragier B; Vanhoutte I; De Paepe A; Poppe B; Claes K
Breast Cancer Res Treat; 2012 Feb; 132(1):87-95. PubMed ID: 21553119
[TBL] [Abstract][Full Text] [Related]
20. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
